UNSPSC 51292001: Adrafinil

This classification denotes an alpha-adrenergic agonist with the molecular formula C15H15NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BI81Z4542G, chemically known as acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)- but generally known as adrafinil, which bears US NIH Compound Identifier 3033226. European Medicines Agency schedules Adrafinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05278MIG. The term ADRAFINIL is an International Non-Proprietary Name.

UNSPSC 51292001 Adrafinil, a Commodity code, nominally identifies a single wakefulness-promoting pharmaceutical agent; however, recent state and local procurement activity under this code shows little alignment with adrafinil specifically. Instead, solicitations tagged to this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs. The mismatch suggests either inconsistent coding practice or category drift in how jurisdictions tag pharmaceutical-related buys. State and local governments using this code are sourcing pharmaceutical products through county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Issuing bodies include Seminole County, Florida (county-level health procurement), the Texas Health and Human Services Commission (state agency), and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (cooperative vehicle spanning multiple states including Oregon).

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB60459723LAS (IFB, response due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS Commission's RFI HHS0017013 (RFI, posted April 3, 2026) is gathering vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (RFP, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with products effective July 1, 2026. None of these solicitations specifically targets adrafinil as a line item, indicating that the code as applied to state and local procurement may not reflect its intended commodity scope.